Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza
Conditions
Interventions
Baloxavir Marboxil
Placebo
Locations
170
United States
Torrance Memorial Medical Center
Torrance, California, United States
Denver Health Medical Center
Denver, Colorado, United States
Atlanta Institute For Medical Research, Inc; DeKalb Medical Pharmacy
Decatur, Georgia, United States
University of Chicago; Oncology Dept
Chicago, Illinois, United States
NorthShore University HealthSystem
Evanston, Illinois, United States
Barnum Medical Research, Inc.
Natchitoches, Louisiana, United States
Start Date
January 8, 2019
Primary Completion Date
March 16, 2020
Completion Date
March 16, 2020
Last Updated
January 6, 2021
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions